Clinical trials for Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)

53 currently recruiting clinical trials
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06235398
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required medullary blasts
< 5 % 5-10 %
Excluded genetic anomalies
NPM1
Excluded previous treatments
Chemotherapy
2 recruiting sites
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 2 Cohorte A
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required medullary blasts
< 5 %
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 2 Cohorte G
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
Erythroid maturation agent
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 2 Cohortes B et C
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 2 Cohortes E et F
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required medullary blasts
< 5 %
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 2 Cohorte D
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
Chronic myelomonocytic leukemia (CMML)
Required number of previous lines of therapy
None
Required medullary blasts
< 5 %
Excluded genetic anomalies
del(5q)
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04419649 #2023-507469-24-00
Partie 1 Escalade de dose
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None 1
Required previous treatments
Systemic Treatment-Naive EPO / Growth factors
Required medullary blasts
< 5 %
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Chemotherapy Erythroid maturation agent Immunomodulator
5 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05980806 #2024-511309-47-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
8 recruiting sites
Karyopharm Therapeutics Inc.
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05037760 #2023-507468-38-00
Bras 1B et 2B
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
Takeda
Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05037760 #2023-507468-38-00
Bras A1 et 2A
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
2 recruiting sites
Takeda